Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.

China’s Ministry of Public Security has made formal bribery charges against UK-based drug maker GlaxoSmithKline and former general manager Mark Reilly and two Chinese executives for bribing non-government agencies and personnel.

With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.

With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.